Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal development
Mucopolysaccharidosis VI (MPS VI) is a rare lysosomal disease arising from impaired function of the enzyme arylsulfatase B (ARSB). This impairment causes aberrant accumulation of dermatan sulfate, a glycosaminoglycan (GAG) abundant in cartilage. While clinical severity varies along with age at first...
Main Authors: | Elizabeth Hwang-Wong, Gabrielle Amar, Nanditha Das, Xiaoli Zhang, Nina Aaron, Kirsten Gale, Nyanza Rothman, Massimo Fante, Andrew Baik, Ajay Bhargava, Arun Fricker, Michelle McAlister, Jeremy Rabinowitz, John Lees-Shepard, Kalyan Nannuru, Aris N. Economides, Katherine D. Cygnar |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2023-11-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.171312 |
Similar Items
-
Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1
by: Senem Aykul, et al.
Published: (2022-06-01) -
Mucopolysaccharidosis
by: Kusumitha Bhakthaganesh, et al.
Published: (2023-01-01) -
Mucopolysaccharidosis
by: Nicole Ruas Guarany PhD, et al.
Published: (2015-11-01) -
Mucopolysaccharidosis VI
by: Harmatz Paul, et al.
Published: (2010-04-01) -
Mucopolysaccharidosis VI
by: Juan Politei MD, et al.
Published: (2015-02-01)